2 results
Maximizing as a predictor of job satisfaction and performance: A tale of three scales
- Nicole M. Giacopelli, Kaila M. Simpson, Reeshad S. Dalal, Kristen L. Randolph, Samantha J. Holland
-
- Journal:
- Judgment and Decision Making / Volume 8 / Issue 4 / July 2013
- Published online by Cambridge University Press:
- 01 January 2023, pp. 448-469
-
- Article
-
- You have access Access
- Open access
- HTML
- Export citation
-
Research on individual differences in maximizing (versus satisficing) has recently proliferated in the Judgment and Decision Making literature, and high scores on this construct have been linked to lower life satisfaction as well as, in some cases, to worse decision-making performance. The current study exported this construct to the organizational domain and evaluated the utility of the three most widely used measures of maximizing in predicting several criteria of interest to organizational researchers: job satisfaction, intentions to quit the organization, performance in the job role, and income. Moreover, this study used relative weight analyses to determine the relative importance of maximizing and two dispositional variables (conscientiousness and core self-evaluations) that are traditionally used to predict these criteria in the organizational literature. Results indicate that relationships between maximizing and these criteria are influenced by the way in which maximizing is measured. Yet, regardless of how it is measured, maximizing is not a particularly strong predictor of these criteria compared to traditional organizational predictors. Limitations and future research directions are discussed.
Chapter 22 - Leukaemias and Lymphomas
- from SECTION 2 - MOLECULAR PATHOLOGY
-
- By Tracey M Wiggill, MB BCh, MMed (Haematology), works as a senior haematopathologist in the Division of Molecular Medicine and Haematology, National Health Laboratory Service and University of the Witwatersrand. She runs the diagnostic immunophenotyping unit at Johannesburg Hospital and her research interests include the molecular diagnostics of haematological malignancies., Nicole S Holland, MB BCh, FCPath (Haematology) is currently employed at the Johannesburg Hospital by the NHLS and is a consultant haematologist in the Division of Molecular Medicine and Haematology at the University of the Witwatersrand., Pascale Willem, qualified as a medical doctor in Paris and specialised in human genetics (Grenobles- Marseille, France). Since 1990 she has run the Somatic Cell Genetics Unit in the Division of Molecular Medicine and Haematology, University of the Witwatersrand. She is involved in cancer research and diagnostics using both molecular genetics and cytogenetics techniques., Lindsay Earlam, MB BCh, FCPath (SA) (Haematology) is currently practising as a consultant haematologist with Lancet Laboratories. Interests include leukaemia/lymphoma immunophenotyping, the molecular pathogenesis of leukaemia and haematological disease in the South African context.
- Edited by Barry Mendelow, University of the Witwatersrand, Johannesburg, Michèle Ramsay, University of the Witwatersrand, Johannesburg, Nanthakumarn Chetty, University of the Witwatersrand, Johannesburg, Wendy Stevens, University of the Witwatersrand, Johannesburg
-
- Book:
- Molecular Medicine for Clinicians
- Published by:
- Wits University Press
- Published online:
- 04 June 2019
- Print publication:
- 01 October 2008, pp 261-270
-
- Chapter
- Export citation
-
Summary
INTRODUCTION
Cells within a multicellular organism are genetically encoded to function in the best interests of the organism as a whole. As such, each cell receives signals from its own cytoplasm and nucleus (such as those provided by the cell cycle machinery) and from outside the cell (such as those provided by cytokines and growth factors). These signals are integrated within the cell to give a cohesive picture of what is required by the organism as a whole. Each cell uses this information to commit to one of three options, namely entry into the cell cycle and proliferation (cell division to create identical daughter cells), cell differentiation (acquisition by the cell of its more specialised functions), or apoptosis (program - med cell death).
A malignancy may arise when any one of these processes escapes its normal control mechanisms, leading to uncontrolled expansion or persistence of an abnormal clone of cells. Malignancies therefore arise by one of three major mechanisms:
• Excessive proliferation of cells
• Failure of cells to differentiate normally
• Failure of cells to undergo normal cell death (apoptosis).
Although one mechanism usually predominates in haematological malignancies, often the other mechanisms contribute to oncogenesis. By definition, a malignancy is monoclonal (i.e. arises from a single abnormal cell), with any abnormalities in the genome being passed from parent to daughter cell. Additional mutations may be acquired by the daughter cells leading to a progressive increase in aggressiveness of the malignancy.
To recapitulate from the previous chapters, two major groups of genes have been shown to play a role in malignancy, namely the oncogenes and the tumour suppressor genes. Proto-oncogenes (normal cellular counterparts of oncogenes) are commonly the cell cycle stimulatory proteins (such as growth factors, growth factor receptors or downstream stimulatory molecules). These molecules cause malignancy through gain of function mutations. Tumour suppressor genes are the cell cycle brakes (or control proteins) and are active at the cell cycle checkpoints. The loss of tumour suppressor function is associated with malignant change.
BASIC PATHOLOGY OF THE LEUKAEMIAS AND LYMPHOMAS
The leukaemias are a broad group of malignancies of cells of haemopoietic lineage, which involve the bone marrow and the peripheral blood.